Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Jul, 2014 | Pages:
153 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)
Seasonal Influenza - Pipeline Review, H2 2014 Summary Global Markets Direct's, 'Seasonal Influenza - Pipeline Review, H2 2014', provides an overview of the Seasonal Influenza's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Seasonal Influenza, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Seasonal Influenza and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Seasonal Influenza - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Seasonal Influenza and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Seasonal Influenza products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Seasonal Influenza pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Seasonal Influenza - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Seasonal Influenza pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 5 List of Figures 6 Introduction 7 Global Markets Direct Report Coverage 7 Seasonal Influenza Overview 8 Therapeutics Development 9 Pipeline Products for Seasonal Influenza - Overview 9 Pipeline Products for Seasonal Influenza - Comparative Analysis 10 Seasonal Influenza - Therapeutics under Development by Companies 11 Seasonal Influenza - Therapeutics under Investigation by Universities/Institutes 15 Seasonal Influenza - Pipeline Products Glance 16 Late Stage Products 16 Clinical Stage Products 17 Early Stage Products 18 Unknown Stage Products 19 Seasonal Influenza - Products under Development by Companies 20 Seasonal Influenza - Products under Investigation by Universities/Institutes 22 Seasonal Influenza - Companies Involved in Therapeutics Development 23 Baxter International Inc. 23 GlaxoSmithKline plc 24 Lentigen Corporation 25 Celltrion, Inc. 26 Liquidia Technologies, Inc. 27 Novartis AG 28 Novavax, Inc. 29 Crucell N.V. 30 OPKO Health, Inc. 31 Medicago Inc. 32 BioDiem Ltd 33 Colby Pharmaceutical Company 34 FluGen, Inc. 35 TechnoVax, Inc. 36 Theraclone Sciences, Inc. 37 NanoBio Corporation 38 Protein Sciences Corporation 39 VaxInnate Corporation 40 Vaxart, Inc. 41 AIMM Therapeutics B.V. 42 Cilian AG 43 AmVac AG 44 TSRL, Inc. 45 Vaxine Pty Ltd 46 AltraVax Inc. 47 Big DNA Ltd. 48 ContraFect Corporation 49 PeptiVir, Inc. 50 Pike Pharma GmbH 51 Codagenix, Inc. 52 Seasonal Influenza - Therapeutics Assessment 53 Assessment by Monotherapy Products 53 Assessment by Combination Products 54 Assessment by Target 55 Assessment by Mechanism of Action 57 Assessment by Route of Administration 59 Assessment by Molecule Type 61 Drug Profiles 63 seasonal influenza vaccine (trivalent) - Drug Profile 63 influenza vaccine, surface antigen, inactivated, adjuvanted with MF59C.1 - Drug Profile 66 inactivated influenza virus surface antigens vaccine - Drug Profile 68 influenza vaccine, surface antigen, inactivated, adjuvanted with MF59C.1 - Drug Profile 69 Subunit Vaccine for Seasonal Influenza - Drug Profile 71 Influenza Vaccine (Trivalent) - Drug Profile 72 Live Attenuated Influenza Vaccine - Drug Profile 73 IC31 Seasonal Influenza Vaccine - Drug Profile 75 JVRS-100 + Fluzone - Drug Profile 76 TCN-032 - Drug Profile 78 CTP-27 - Drug Profile 80 Influenza Vaccine (Quadrivalent) - Drug Profile 81 Seasonal Flu Vaccine - Drug Profile 83 Monoclonal Antibody for Seasonal Influenza - Drug Profile 84 Subunit Vaccine for Seasonal Influenza - Drug Profile 85 Immunose FLU - Drug Profile 87 LIQ-001 - Drug Profile 89 TAK-850 - Drug Profile 90 FluCell - Drug Profile 91 Influenza Vaccine (Trivalent) - Drug Profile 92 NB-1008 - Drug Profile 93 VXAA-1.1 - Drug Profile 94 VAX-2012Q - Drug Profile 95 Seasonal Flu Vaccine - Drug Profile 96 Flu Vaccine - Drug Profile 97 LG-811 - Drug Profile 98 seasonal influenza vaccine (trivalent) - Drug Profile 99 TVX-001 - Drug Profile 102 Monoclonal Antibodies to Target Hemagglutinin for Seasonal Influenza and Pandemic Influenza - Drug Profile 103 CF-404 - Drug Profile 104 AMV-401 - Drug Profile 105 CiFlu - Drug Profile 106 Bispecific Monoclonal Antibody for Seasonal and Pandemic Influenza - Drug Profile 108 TSR-026 - Drug Profile 109 Seasonal Influenza Vaccine - Drug Profile 110 IKT-041 - Drug Profile 111 influenza vaccine (trivalent) - Drug Profile 112 Recombinant Vector Vaccine for H3N2 Seasonal Influenza - Drug Profile 113 PVI-1000 - Drug Profile 114 Influ-nRNA - Drug Profile 115 A-06 - Drug Profile 116 BDNA-002 - Drug Profile 117 Respiratory Syncytical Virus + Influenza Vaccine - Drug Profile 118 VH-244 - Drug Profile 119 Pan-Flu - Drug Profile 121 CTP-25 - Drug Profile 122 Universal Vaccine for Seasonal and Pandemic Influenza - Drug Profile 123 TSR-462 - Drug Profile 124 Small Molecules to Inhibit Viral Polymerase for Influenza - Drug Profile 125 seasonal influenza vaccine - Drug Profile 126 Seasonal Influenza - Recent Pipeline Updates 127 Seasonal Influenza - Dormant Projects 139 Seasonal Influenza - Discontinued Products 140 Seasonal Influenza - Product Development Milestones 141 Featured News & Press Releases 141 Appendix 148 Methodology 148 Coverage 148 Secondary Research 148 Primary Research 148 Expert Panel Validation 148 Contact Us 149 Disclaimer 149
List of Tables Number of Products under Development for Seasonal Influenza, H2 2014 13 Number of Products under Development for Seasonal Influenza - Comparative Analysis, H2 2014 14 Number of Products under Development by Companies, H2 2014 16 Number of Products under Development by Companies, H2 2014 (Contd..1) 17 Number of Products under Development by Companies, H2 2014 (Contd..2) 18 Number of Products under Investigation by Universities/Institutes, H2 2014 19 Comparative Analysis by Late Stage Development, H2 2014 20 Comparative Analysis by Clinical Stage Development, H2 2014 21 Comparative Analysis by Early Stage Development, H2 2014 22 Comparative Analysis by Unknown Stage Development, H2 2014 23 Products under Development by Companies, H2 2014 24 Products under Investigation by Universities/Institutes, H2 2014 26 Seasonal Influenza - Pipeline by Baxter International Inc., H2 2014 27 Seasonal Influenza - Pipeline by GlaxoSmithKline plc, H2 2014 28 Seasonal Influenza - Pipeline by Lentigen Corporation, H2 2014 29 Seasonal Influenza - Pipeline by Celltrion, Inc., H2 2014 30 Seasonal Influenza - Pipeline by Liquidia Technologies, Inc., H2 2014 31 Seasonal Influenza - Pipeline by Novartis AG, H2 2014 32 Seasonal Influenza - Pipeline by Novavax, Inc., H2 2014 33 Seasonal Influenza - Pipeline by Crucell N.V., H2 2014 34 Seasonal Influenza - Pipeline by OPKO Health, Inc., H2 2014 35 Seasonal Influenza - Pipeline by Medicago Inc., H2 2014 36 Seasonal Influenza - Pipeline by BioDiem Ltd, H2 2014 37 Seasonal Influenza - Pipeline by Colby Pharmaceutical Company, H2 2014 38 Seasonal Influenza - Pipeline by FluGen, Inc., H2 2014 39 Seasonal Influenza - Pipeline by TechnoVax, Inc., H2 2014 40 Seasonal Influenza - Pipeline by Theraclone Sciences, Inc., H2 2014 41 Seasonal Influenza - Pipeline by NanoBio Corporation, H2 2014 42 Seasonal Influenza - Pipeline by Protein Sciences Corporation, H2 2014 43 Seasonal Influenza - Pipeline by VaxInnate Corporation, H2 2014 44 Seasonal Influenza - Pipeline by Vaxart, Inc., H2 2014 45 Seasonal Influenza - Pipeline by AIMM Therapeutics B.V., H2 2014 46 Seasonal Influenza - Pipeline by Cilian AG, H2 2014 47 Seasonal Influenza - Pipeline by AmVac AG, H2 2014 48 Seasonal Influenza - Pipeline by TSRL, Inc., H2 2014 49 Seasonal Influenza - Pipeline by Vaxine Pty Ltd, H2 2014 50 Seasonal Influenza - Pipeline by AltraVax Inc., H2 2014 51 Seasonal Influenza - Pipeline by Big DNA Ltd., H2 2014 52 Seasonal Influenza - Pipeline by ContraFect Corporation, H2 2014 53 Seasonal Influenza - Pipeline by PeptiVir, Inc., H2 2014 54 Seasonal Influenza - Pipeline by Pike Pharma GmbH, H2 2014 55 Seasonal Influenza - Pipeline by Codagenix, Inc., H2 2014 56 Assessment by Monotherapy Products, H2 2014 57 Assessment by Combination Products, H2 2014 58 Number of Products by Stage and Target, H2 2014 60 Number of Products by Stage and Mechanism of Action, H2 2014 62 Number of Products by Stage and Route of Administration, H2 2014 64 Number of Products by Stage and Molecule Type, H2 2014 66 Seasonal Influenza Therapeutics - Recent Pipeline Updates, H2 2014 131 Seasonal Influenza - Dormant Projects, H2 2014 143 Seasonal Influenza - Discontinued Products, H2 2014 144
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
